Abnormal expression of ADAR1 isoforms in Chinese pediatric acute leukemias

CH Ma, JH Chong, Y Guo, HM Zeng, SY Liu… - Biochemical and …, 2011 - Elsevier
CH Ma, JH Chong, Y Guo, HM Zeng, SY Liu, LL Xu, J Wei, YM Lin, XF Zhu, GG Zheng
Biochemical and biophysical research communications, 2011Elsevier
The posttranscriptional RNA editing by the type 1 adenosine deaminase acting on RNAs
(ADAR1), expressed as p110 and p150 isoforms, is important for both physiological and
pathological processes. Their expression and significance in leukemias remain unknown.
Here, we investigated the expression of ADAR1 in Chinese pediatric acute leukemias by
real-time PCR and Western blot. The results showed that significant high expression of p110
was detected in leukemias, especially in B-ALL, whereas a slight increase of p150 could be …
The posttranscriptional RNA editing by the type 1 adenosine deaminase acting on RNAs (ADAR1), expressed as p110 and p150 isoforms, is important for both physiological and pathological processes. Their expression and significance in leukemias remain unknown. Here, we investigated the expression of ADAR1 in Chinese pediatric acute leukemias by real-time PCR and Western blot. The results showed that significant high expression of p110 was detected in leukemias, especially in B-ALL, whereas a slight increase of p150 could be observed. Furthermore, the decrease of p110 expression was observed in B-ALL patients achieving complete remission. Moreover, among prognostic risk groups in ALL, the highest expressions of p110 and p150 were detected in standard-risk group, whereas their lowest expressions were in high-risk group. This observation was further confirmed in comparisons between good and poor prognostic groups based on prognostic related clinical features. These results demonstrated that ADAR1 isoforms showed different expression patterns, suggesting that they might play different roles in pediatric leukemias. Our results will help us for the better understanding of RNA editing, exploring the potential target for the treatment, and making prognostic evaluation in childhood leukemias.
Elsevier